Portola Pharmaceuticals Inc.'s clinical results from a study will be presented during the International Conference on Malignant Lymphoma.
The study has tested cerdulatinib in individuals with relapsed/refractory b-cell malignancies. The medication is an oral SYK/JAK kinase inhibitor that works by preventing two of the signaling pathways which are responsible for the growth of cancer cells.
The conference will be held June 14-17 in Lugano, Switzerland. Portola is slated to present The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study in Patients with Relapsed/Refractory B-Cell Malignancies on June 15 at Lugano University.
Alerts Sign-up